218 related articles for article (PubMed ID: 18280815)
1. PCSK9: an enigmatic protease.
Lopez D
Biochim Biophys Acta; 2008 Apr; 1781(4):184-91. PubMed ID: 18280815
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
Lopez D
Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
[TBL] [Abstract][Full Text] [Related]
3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
4. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
7. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
[TBL] [Abstract][Full Text] [Related]
8. PCSK9: a key modulator of cardiovascular health.
Seidah NG; Awan Z; Chrétien M; Mbikay M
Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
[TBL] [Abstract][Full Text] [Related]
9. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
[TBL] [Abstract][Full Text] [Related]
10. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis.
Mousavi SA; Berge KE; Leren TP
J Intern Med; 2009 Dec; 266(6):507-19. PubMed ID: 19930098
[TBL] [Abstract][Full Text] [Related]
11. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice.
Denis M; Marcinkiewicz J; Zaid A; Gauthier D; Poirier S; Lazure C; Seidah NG; Prat A
Circulation; 2012 Feb; 125(7):894-901. PubMed ID: 22261195
[TBL] [Abstract][Full Text] [Related]
12. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).
Schulz R; Schlüter KD; Laufs U
Basic Res Cardiol; 2015 Mar; 110(2):4. PubMed ID: 25600226
[TBL] [Abstract][Full Text] [Related]
13. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
Maxwell KN; Breslow JL
Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
[TBL] [Abstract][Full Text] [Related]
14. Unravelling the functional significance of PCSK9.
Lambert G
Curr Opin Lipidol; 2007 Jun; 18(3):304-9. PubMed ID: 17495605
[TBL] [Abstract][Full Text] [Related]
15. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of PCSK9 function.
Lambert G; Charlton F; Rye KA; Piper DE
Atherosclerosis; 2009 Mar; 203(1):1-7. PubMed ID: 18649882
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
18. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
[TBL] [Abstract][Full Text] [Related]
19. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
Schiele F; Park J; Redemann N; Luippold G; Nar H
J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]